© 1996 Nature Publishing Group http://www.nature.com/naturegenetics

BRCA2 mutations in primary breast and ovarian cancers

Johnathan M. Lancaster[1], Richard Wooster[2], Jonathon Mangion[2], Catherine M. Phelan[3,4,5], Charles Cochran[1], Curtis Gumbs[5], Sheila Seal[2], Rita Barfoot[2], Nadine Collins[2], Graham Bignell[2], Sandeep Patel[2], Rifat Hamoudi[2], Catharina Larsson[3], Roger W. Wiseman[1], Andrew Berchuck[7], J. Dirk Iglehart[5], Jeffrey R. Marks[5], Alan Ashworth[6], Michael R. Stratton[2] & P. Andrew Futreal[5,7,8]

[1]*Laboratory of Molecular Carcinogenesis, MD C4-06, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, North Carolina, USA.*
[2]*Section of Molecular Carcinogenesis, Institute of Cancer Research, Haddow Laboratories, Surrey, UK and Chester Beatty Laboratories, Fulham Road, London, UK*
[3]*Department of Molecular Medicine, Endocrine Tumor Unit, Karolinska Hospital, Stockholm, Sweden*
[4]*Department of Human Genetics and Medicine, McGill University, Montreal General Hospital, Montreal, Quebec, Canada*
[5]*Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710-2611, USA*
[6]*CRC Center for Molecular Biology, Institute for Cancer Research, Haddow Laboratories, Surrey, UK and Chester Beatty Laboratories, Fulham Road, London, UK*
[7]*Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina, USA*
[8]*Department of Genetics, Duke University Medical Center, Durham, North Carolina, USA*

Correspondence should be addressed to P.A.F.
e-mail: futre001@mc.duke.edu

The second hereditary breast cancer gene, *BRCA2*, was recently isolated[1]. Germline mutations of this gene predispose carriers to breast cancer, and, to a lesser extent, ovarian cancer. Loss of heterozygosity (LOH) at the *BRCA2* locus has been observed in 30–40% of sporadic breast and ovarian tumours, implying that *BRCA2* may act as a tumour suppressor gene in a proportion of sporadic cases [2–5]. To define the role of *BRCA2* in sporadic breast and ovarian cancer, we screened the entire gene for mutations using a combination of techniques in 70 primary breast carcinomas and in 55 primary epithelial ovarian carcinomas. Our analysis revealed alterations in 2/70 breast tumours and none of the ovarian carcinomas. One alteration found in the breast cancers was a 2-basepair (bp) deletion (4710delAG) which was subsequently shown to be a germline mutation, the other was a somatic missense mutation (Asp3095Glu) of unknown significance. Our results suggest that *BRCA2* is a very infrequent target for somatic inactivation in breast and ovarian carcinomas, similar to the results obtained for *BRCA1*.

We analysed genomic DNA from 70 breast and 55 epithelial ovarian cancers for *BRCA2* mutations. Thirty-four of the breast and 18 of the ovarian tumours (56% and 53% respectively of informative cases) showed LOH in the *BRCA2* region, using the markers *D13S260, D13S171, D13S260,* and *D13S153*. The latter marker is intragenic to the *RB1* gene. All tumours analysed which were informative for both the *BRCA2* and the *RB1* regions of 13q show concomittant LOH (data not shown). The complete coding region was screened in each sample using both single strand conformation analysis (SSCA) and denaturing gel deletion analysis. In addition, exons 10, 11 and 27 were also screened by the protein truncation test (PTT). Potential sequence alterations represented by aberrant bands were characterized by direct sequencing in all cases.

Table 1 ***BRCA2*** **mutations in primary breast cancer**

Patient no.	Age	Mutation	Effect	Germline/ somatic
19	59	4710delAG	frameshift	germline
6	74	C to A	Asp3095Glu	somatic

Sequence alterations were identified in 2/70 breast tumours (Table 1), but none of the 55 ovarian samples. An SSCA shift in exon 11 was detected in breast carcinoma sample #19 (Fig. 1). This fragment, along with the corresponding fragment from the patient's normal lymphocyte DNA and a healthy control, were sequenced directly. A 2-bp AG deletion was detected, corresponding to a 4710delAG mutation. This deletion produces a frameshift leading to a predicted premature termination codon 2 amino acids downstream. The deletion was present in the patient's germline (Fig. 1*b*). No family history of cancer had been reported by this individual, who was diagnosed at age 59 with a unilateral infiltrating ductal carcinoma. In breast carcinoma sample #6 a somatic alteration was detected. This alteration was found to be a C to A transversion in exon 25 resulting in an aspartate to glutamate amino acid change at codon 3095 (Fig. 2). The change was not present in the patients lymphocyte DNA, nor in over 300 control chromosomes. Six different highly polymorphic microsatellite markers on chromosomes 16 and 17 confirmed that the tumour and lymphocyte DNA came from the same patient (data not shown). This tumour sample had LOH in the *BRCA2* region and it was the aberrant glutamate residue that was retained in the tumour. This patient had a unilateral infiltrating ductal adenocarcinoma diagnosed at age 74. The significance of this amino acid change is unclear. Additionally, several sequence variants were detected via SSCA[6].

The lack of *BRCA2* mutations in sporadic breast and ovarian cancers is very reminiscent of the results obtained for *BRCA1*[7–10]. Similar to the observation for *BRCA1*, the region containing *BRCA2* undergoes LOH in a fraction of breast and ovarian carcinomas[8]. The



Fig. 1 *a*, SSCA autoradiogram showing shift in Patient 19 in lane 3. *b*, ABI electropherograms showing germline delAG in patient 19. The antisense strand is shown. MC19T, DNA from patient's tumour. MC19N, DNA from patient's peripheral blood. Control is unrelated normal blood DNA.

© 1996 Nature Publishing Group http://www.nature.com/naturegenetics



Fig. 2 *a*, Autoradiogram SSCA showing shift of tumour 6 in lane 3. *b*, Electropherogram showing sequence of missense mutation in tumour 6. Antisense strand is shown for both patients' tumour and normal blood DNA. The G to T transversion in tumour DNA shown in the right panel results in a GAC to GAA/ Asp to Glu amino acid substitution on the sense strand. This missense change was not present in the matching peripheral blood DNA from the same patient in the left panel.

Table 2*a* *BRCA2* PCR primers

Exon	Primers	Sequence (5'→3')	Exon	Primers	Sequence (5'→3')
2	JAD46	F-CAAGCATTGGAGGAATATCG R-GTTTATGGTTCTAAGCAACAC		JAD8	AACCAGAAAGAATAAATACT CCTCAACGCAAATATCTTCAT
3	JAD47	CACAAATTTGTCTGTCACTGG ATTGCATTACTTACCTAAGTC		JAD7	TTCCAAAGTAATATCCAATGTA ATTTTTGATTTATTCTCGTTGTT
4	JAD48	ATCCAGAGTATATACATTCTC GATCTTCTACCAGGCTCTTAG		JAD6	AAGTGAAAGACATATTTACAGACAG TATGAAGCTTCCCTATACT
5,6	JAD 52	AAAATAACCTAAGGGATTTGC CAAATTCTCAATTACTAAGTC		JAD5	CACCTTGTGATGTTAGTTTG TTGGGATATTAAATGTTCTGGAGTA
7	JAD49	CAATTCAGTAAACGTTAAGTG AACAGAAGTATTAGAGATGAC		JAD4	AAGTAACGAACATTCAGACC CTGGGTTTCTCTTATCAACAGCA
8	JAD50	CATGTAATCAAATAGTAGATGTGC CTCAAAGGCTTAGATAAATTACAG		JAD3	GTCTTCACTATTCACCTACG AGTGAGACTTTGGTTCCTAAT
9	JAD51	GCATTGAGAGTTTTTATACTAGTG ACCTGTAGTTCAACTAAACAG		JAD2	TTCAACAAGACAAACAACAGT GTCAGTTCATCATCTTCCATAAA
10	JAD54F JAD23R	GCTTCTGTTTTATACTTTAACAGG GATCAGTATCATTTGGTTCCAC		JAD1	CTTACTCCAAAGATTCAGAAAACTAC AGCATACCAAGTCTACTGAATAAAC
	JAD20F JAD23R	CAAAGACCACATTGGAAAGTC GATCAGTATCATTTGGTTCCAC	12	JAD30	ATAAAACTGATATTATTTGCC TCCACCTGAGGTCAGAAT
	JAD24	AAGCAAACGCTGATGAATGTG TGGTCACATGAAGAAATATGC	13	S1237 S1236	TAAAGCCTATAATTGTCTCA CTTCTTAACGTTAGTGTCATT
	JAD25	CAGGTCTAAATGGAGCCCAG GAGAAGTTCCAGATATTGCC	14	A45 A44	AAGGAACGTCAAGAGATACAG GGTTGGTCTGCCTGTAGTAAT
	JAD26	CATCTTGAATCTCATACAGAC GACATAAGGAGTCCTCCTTC		S1239 S1238	CTTCAAGCAATTTAGCAGTTTCAGG GCTGCTTGATTGGAGTTGTT
	JAD27F JAD20R	AAGCCTCTGAAAGTGGACTG GCAAATGTAAGTGGTGCTTC	15	JAD31	ATTTAATTACAAGTCTTCAG ACTCTGTCATAAAAGCCATC
11	JAD53	GATGGTACTTTAATTTGTCAC CAAGATCCTGAGAGATTACTG	16	JAD32	TATTTTGTGTAGCTGTATACG AGGGAATACATAAAAGTTAAC
	JAD22	GCTCTTTTGGGACAATTCTG ATAAAAGACTTTTCTGGGATTG	17	JAD33	ATTCAGTATCATCCTATGTGG TATGATTACGTAATGTAATGC
	JAD21	TGGAATACAGTGATACTGAC TTTTCAGGTGGCAACAGCTC	18	JAD34	GAATTCTAGAGTCACACTTCC ATCTAACTGGGCCTTAACAGC
	JAD19	CCCATGGAAAAGAATCAAGATG GTTCCTTAGTATTCCTAAAGC		JAD35	TGGCCATTATTGAACTTACAG AATTGAGCATCCTTAGTAAGC
	JAD18	TGTCTTCCAAGTAGCTAATG CTGTGATTTGAAATTGGACC	19	JAD36	GAATGAAAACTCTTATGATATCTG AAGAGACCGAAACTCCATCTC
	JAD17	ACATGAACAAATGGGCAGGAC TGGTTTGAATTAAAATCCTGC	20	JAD37	CACTGTGCCTGGCCTGATAC AGTCTCTAAGACTTTGTTCTC
	JAD16	GTCATATAACCCCTCAGATG CTGTACCTTCAAATTGCTTGC	21	JAD53	TAAATCTCCCTTCTTTGGGTG TTCCTTCTTGTGATGGCCAG
	JAD15	CGATTGGTCAGGTAGACAGC CTCTGCAGAAGTTTCCTCAC	22	JAD38	TCTAGTTACAATAGATGGAAC AATCATTTTGTTAGTAAGGTC
	JAD14	TGTTTCTACTGAAGCTCTGC GTTATCTTCATTTTCAGTATTTCTC	23	JAD39	GCATCTTTCTCATCTTTCTCC TGAAATAAAATTTCATCTGAAAAC
	JUL5 F3 JUL5 R4	TTGAAATGACTACTGGCAC CCTTCATAAACTGGCCAGATAAT	24	JAD40	TTGTTAGTTTATGGAATCTCC TAATCATAAGAGATTTTAAAAGAC
	JAD13	TGTCTTAAATTATCTGGCCAG AAATGACTCTTTGGCGACAC	25	JAD41	TTCCATTCTAGGACTTGCCC GTGGTGATGCTGAAAAGTAAC
	JAD12	AGATTTTGAGACTTCTGATAC TCCAGTACCAACTGGGACAC	26	JAD42	TTTATAAAGCAGCTTTTCCAC ATACTTCTTATAATATTCCTTGAG
	JUL5 F1 JUL5 R1	TGGACATTCTAAGTTATGAGG ATTTCACTAGTACCTTGCTCTTTT	27	JAD43	ACATAATTATGATAGGCTACG AAATGTACAAATGGGACTAAC
	JAD11	TGATGAAAAAGAGCAGGTAC ACAAGGTTTTTATCATTATTG		JAD44	AGCCTTGGATTTCTTGAGTAG TCCTAGTGGATTCACTGACAG
	JAD10	CTGCCCCAAAGTGTAAAGAAAT AATGACTGAATAAGGGGACTGAT		JAD45	TCTTTTGTCTGGTTCAACAGG AAGCGTCAATAATTTATTGTC
	JAD9	TCCTGCAACTTGTTACAC GATTTTTGTCATTTTCAGC			

relatively close proximity of the *RB1* gene could be driving the majority of the LOH seen in these cases. Our study set contained no tumours that demonstrated loss at one region versus the other when informative for both. However, for breast and particularly ovarian cancers, there is evidence to suggest that the *RB1* gene can be excluded from the regions of loss in some cases and is not always targeted for inactivation in cases with large scale losses on 13q (refs 3, 5, 11). Our screening set contained both tumours selected for LOH in the *BRCA2* region as well as unselected cancer cases to increase the likelihood of finding mutations. Additionally, we employed three complementary techniques in screening for mutations, and thus feel that few coding region mutations have been missed. The two alterations found were both from tumours showing LOH. One case was a germline frameshift deletion which was retained in the tumour, the other a somatic missense mutation which was also retained in the tumour. The significance of the latter somatic mutation is unclear. Our data showing infrequent mutations in sporadic tumours suggests that if *BRCA2* plays a significant role in tumourigenesis in the non-hereditary forms of these cancers, it is through a mechanism other than structural mutation. Further, combined with the data on somatic mutations of *BRCA1* in sporadic breast and ovarian cancers, the evidence suggests that hereditary breast cancer (and ovarian cancer in the context of breast/ovarian cancer syndromes) may be fundamentally different diseases at the molecular genetic level. This is not to suggest that these genes play no role in the development of non-hereditary breast and ovarian cancers. Recent evidence would suggest that subcellular localization and/or expression levels may be critical in *BRCA1* involvement in cancer[12,13]. Given the results presented here, parallel studies on the expression, localization and, ultimately, normal function of *BRCA2* are paramount.

Methods

Samples. Tumour tissue and matched blood lymphocytes were obtained from patients treated at Duke University Medical Center, USA, and the Royal Marsden Hospital, England and from the Gynecologic Oncology Group/Cooperative Human Tissue network ovarian tissue bank (USA). Tissues was obtained under general consent for discarded tissue and tumour/white cell banking. Genomic DNA was obtained from tumour tissue and blood using standard procedures. The breast cancers were all infiltrating ductal carcinomas with the exception of two pure intraductal carcinomas. The mean age of onset for the breast study set was 53. The ovarian carcinomas were of mixed histology, the majority being papillary serous (90%), and the mean age of onset for the tumours studied was 58. There were no cases of either bilateral breast or dual primary breast/ovarian cancer in the study set.

Single strand conformation analysis. The entire coding region, including intron/exon borders, was examined by SSCA (using primers given in Table 2*a*). Genomic DNA (20 ng) was amplified using primers under the following standard PCR conditions: 50 mM KCl, 10 mM Tris-HCl, pH 9.0, 1.5 mM $MgCl_2$ (Promega), 0.2 mM dTTP, dCTP and dGTP, 0.05 mM dATP, and (α-P^{32})dATP (Amersham) at 1 μCi/reaction and 2 U *Taq* DNA Polymerase (Promega) in a final volume of 10 μl. Thermocycling conditions consisted of 30 cycles of 30 s at 94 °C, 30 s at 55 °C, and 30 s at 72 °C, followed by one cycle of 3 min extension at 72 °C in a 9600 Thermocycler (Perkin-

© 1996 Nature Publishing Group http://www.nature.com/naturegenetics

Table 2b *BRCA2* PTT primers

Exon	Primers	PTT primer sequence[a] (5'→3')
10	JAD20F × JAD20R	JL-PTTH GAAACAGTTGTAGATACCTCTGAAGA
11	JAD54F × JAD17R	JL-PTTD GATTCTGAAGAACCAACTTTGTCC
11	JAD17F × JAD14R	JL-PTTF GAAATCAAGCTCTCTGAACATAAC
11	JAD14F × JAD12R	JL-PTTE GAAACTTCTGCAGAGGTACATCCA
11	JAD12F × JAD8R	JL-PTTA GACATTCTAAGTTATGAGGA
11	JAD9F × JAD5R	JL-PTTB GGTCAACCAGAAAGAATAAATACT
11	JAD5F × JAD2R	JL-PTTG GGGAAGCTTCATAAGTCAGTC
27	JAD43F × JAD45R	JL-PTTJ TCTTCTCCTAATTGTGAGATA

[a]Each PTT primer is preceded by the T7/Kozak sequence 5'–GGATCCTAATACGACTCACTATAGGGAGACCACCATG–3'.

Elmer). PCR product (4 µl) was diluted in 56 µl of loading buffer (95% formamide, 10 mM NaOH, 0.05% bromophenol blue, 0.05% xylene cyanol), denatured at 94 °C for 5 min, and rapidly cooled on ice. A sample of 4 µl was electrophoresed through a 0.5× MDE gel (AT Biochem) containing 0.6× TBE buffer, at room temperature for 14–18 h at 8 W, dried, and autoradiographed for 1–18 h. Migration shift analysis was also used for detection of small deletions/insertions[1]. Samples were amplified as described above and were run through 5% denaturing sequencing gels at 70 W, dried and autoradiographed for 1–4 h.

Protein truncation test. Exons 10, 11 and 27, which represent 64% of the coding region, were amplified in 8 segments by the polymerase chain reaction (PCR) using primers given in Table 2*b*. A 1 µl aliquot of each of these primary templates was subjected to 10 additional cycles of PCR, in a reaction mixture containing a modified primer carrying a T7 promoter and eukaryotic translation initiation sequence in place of the forward primer. A 20 µl reaction mix containing 6 µl of the secondary PCR product, 1.6 µl of ^{35}S-methionine (1,000 Ci/mmol, Amersham), 0.8 ul RNAsin (recombinant 40 U/µl), 0.4 µl TnT T7 RNA Polymerase, 0.2 µl amino acid Methionine(-) Mix, and 5.0 µl TnT Rabbit reticulocyte lysate (Promega), was incubated at 30 °C for 1 h. This product (6 µl) was electrophoresed on a 10–20% SDS-polyacrylamide Ready-Gel (Biorad), fixed, dried and autoradiographed for 3–18 h.

DNA sequence analysis. Sequencing templates were produced for samples showing aberrant mobility on SSCA or PTT. Aberrant SSCA bands were cut from the MDE gel and eluted in 100 µl of dH_20 for 90 min at 37 °C. An additional 30 cycles of PCR was then carried out to amplify the DNA eluted from the gel slice. A parallel PCR was carried out to amplify genomic DNA from the same patient using the same primers. PCR products were purified using the Wizard PCR Prep DNA Purification System (Promega) and sequenced using a PRISM DyeDeoxy Terminator Cycle Sequencing kit and a 373 automated fluorescent sequencer (Applied BioSystems), according to manufacturer's instructions.

Acknowledgements

We thank P. Biggs, N. Rahman and B. Gusterson for assistance. This work was funded in part by the NCI/Duke University Specialized Program of Research Excellence (SPORE) in breast cancer P50-CA68438, NIH/NCI grant R21-CA68348, NIH grant 1R21-CA66228, the National Insititutes of Environmental Health Sciences, the Cancer Research Campaign, BREAKTHROUGH Breast Cancer Charity and Jean Rook Appeal, the US Army, the Institute for Cancer Research. C.M.P. and C.L. were funded by the Swedish Cancer Foundation.

Received 28 February; accepted 29 March 1996.

1. Wooster, R. *et al.* Identification of the breast cancer susceptibility gene *BRCA2*. *Nature* **378**, 789–792 (1995).
2. Lundberg, C. *et al.* Loss of heterozygosity in human ductal breast tumours indicates a recessive mutation on chromosome 13. *Proc. Natl. Acad. Sci. USA* **84**, 2372–2376 (1987)
3. Kim, T.M. *et al.* Loss of heterozygosity on chromosome 13 is common only in the biologically more aggressive subtypes of ovarian eptithelial tumors and is associated with normal retinoblastoma expression. *Cancer Res.* **54**, 605–609 (1994).
4. Collins, N. *et al.* Consistent loss of the wild type allele in breast cancers from a family linked to the *BRCA2* gene chromosome 13q12–13. *Oncogene* **10**, 1673–1675 (1995).
5. Cleton-Jansen, A.M. *et al.* Loss of heterozygosity in sporadic breast tumors at the *BRCA2* locus on chromosome 13q12–13. *Br. J. Cancer* **72**, 1241–1244 (1995).
6. Phelan, C.M. *et al.* Mutation analysis of the *BRCA2* gene in 49 site-specific breast cancer families. *Nature Genet.* **13**, 120–122 (1996).
7. Futreal, P.A. *et al.* *BRCA1* mutations in primary breast and ovarian carcinomas. *Science* **266**, 120–122 (1994).
8. Merajver, S.A. *et al.* Somatic mutations in the *BRCA1* gene in sporadic ovarian tumours. *Nature Genet.* **9**, 439–443 (1995).
9. Hosking, L. *et al.* A somatic *BRCA1* mutation in an ovarian tumour. *Nature Genet.* **9**, 343–344 (1995).
10. Takahashi, H. *et al.* Mutation analysis of the *BRCA1* gene in ovarian cancers. *Cancer Res.* **55**, 2998–3002 (1995).
11. Kerangueven, F. *et al.* Patterns of loss of heterzygosity at loci from chromosome arm 13q suggest a possible involvement of *BRCA2* in sporadic breast tumors. *Genes Chrom. Cancer* **13**, 291–294 (1995).
12. Chen, Y, *et al.* Aberrant subcellular localization of *BRCA1* in breast cancer. *Science* **270**, 789–791, (1995).
13. Thompson, M.E., Jensen, R.A., Obermiller, P.S., Page, D.L. & Holt, J.T. Decreased expression of *BRCA1* accelerates growth and is often present during sporadic breast cancer progression. *Nature Genet.* **9**, 444–450 (1995).